Home » Stocks » Summit Therapeutics

Summit Therapeutics PLC (SMMT)

Stock Price: $3.66 USD 0.03 (0.83%)
Updated Aug 7, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 246.07M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 67.23M
EPS (ttm) 1.23
PE Ratio 2.98
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $3.66
Previous Close $3.63
Change ($) 0.03
Change (%) 0.83%
Day's Open 3.64
Day's Range 3.61 - 3.68
Day's Volume 18,150
52-Week Range 1.18 - 5.49

More Stats

Market Cap 246.07M
Enterprise Value 183.25M
Earnings Date (est) Aug 27, 2020
Ex-Dividend Date n/a
Shares Outstanding 67.23M
Float 24.81M
EPS (basic) n/a
EPS (diluted) 1.23
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield 33.61%
FCF Yield n/a
Payout Ratio n/a
Shares Short 58,633
Short Ratio 1.36
Short % of Float n/a
Beta 0.64
PE Ratio 2.98
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 3.42
Revenue n/a
Operating Income n/a
Net Income n/a
Free Cash Flow n/a
Net Cash 62.81M
Net Cash / Share 0.93
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -36.13%
ROE -77.76%
ROIC n/a
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (1)

Buy 1
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$4.00*
Low
4.00
Current: $3.66
High
4.00
Target: 4.00
*Average 12-month USD price target from 1 stock analysts.

Financial Performance

Financial numbers in millions GBP.

Financial Overview

Year2018201720162015201420132012
Revenue43.0112.362.30----
Revenue Growth247.99%436.46%-----
Gross Profit43.0112.362.30----
Operating Income2.67-25.83-24.85-20.35-12.23-6.71-4.58
Net Income7.49-20.16-21.37-20.14-11.38-6.09-4.23
Shares Outstanding73.5661.8461.2941.1258.3758.37-
Earnings Per Share0.09-0.31-0.35-0.34-0.29-0.30-0.27
Operating Cash Flow-26.66-14.5412.14-17.18-11.67-5.87-3.19
Capital Expenditures-0.12-0.36-0.08-0.07-0.040.07-0.03
Free Cash Flow-26.78-14.9012.06-17.25-11.70-5.80-3.22
Cash & Equivalents26.8620.1028.0616.3011.272.030.00
Total Debt1.014.385.925.032.16--
Net Cash / Debt25.8515.7322.1411.279.112.030.00
Assets60.6455.1737.5925.0619.407.30-
Liabilities18.1058.3341.088.986.432.53-
Book Value42.54-3.15-3.4916.0812.964.76-
Numbers in millions GBP, except per-share numbers.

Company Profile

Company Details

Full Name Summit Therapeutics PLC
Country United Kingdom
Employees 70
CEO Robert W. Duggan

Stock Information

Ticker Symbol SMMT
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: SMMT

Description

Summit Therapeutics plc, a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States, Latin America, and Europe. It conducts clinical programs focusing on the Clostridium difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. It also develops DDS-01 series to treat infection caused by the bacteria Neisseria gonorrhoeae through Discuva platform; and DDS-04 series to treat Enterobacteriaceae. The company was formerly known as Summit Corporation plc and changed its name to Summit Therapeutics plc in February 2015. Summit Therapeutics plc was founded in 2003 and is based in Abingdon, the United Kingdom.